1.69
Precedente Chiudi:
$1.74
Aprire:
$1.76
Volume 24 ore:
231.42K
Relative Volume:
0.69
Capitalizzazione di mercato:
$22.86M
Reddito:
$1.89M
Utile/perdita netta:
$-17.92M
Rapporto P/E:
-0.2526
EPS:
-6.69
Flusso di cassa netto:
$-15.62M
1 W Prestazione:
+9.74%
1M Prestazione:
+36.29%
6M Prestazione:
+0.60%
1 anno Prestazione:
-46.69%
Longeveron Inc Stock (LGVN) Company Profile
Nome
Longeveron Inc
Settore
Industria
Telefono
305-302-7158
Indirizzo
1951 NW 7TH AVENUE, MIAMI
Confronta LGVN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
LGVN
Longeveron Inc
|
1.69 | 25.07M | 1.89M | -17.92M | -15.62M | -6.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-06 | Iniziato | ROTH MKM | Buy |
Longeveron Inc Borsa (LGVN) Ultime notizie
What analysts say about Longeveron Inc. stockPowerful market insights - PrintWeekIndia
What risks could impact Longeveron Inc. stock performanceMarket-leading capital gains - jammulinksnews.com
Longeveron Inc. Stock Analysis and ForecastFree Wealth Management Insights - Autocar Professional
Is Longeveron Inc. a good long term investmentExplosive earnings growth - jammulinksnews.com
How Longeveron Inc. stock performs during market volatilityIntraday Trade Ideas - Newser
What drives Longeveron Inc. stock priceHigh-impact investment strategies - jammulinksnews.com
Published on: 2025-07-22 07:30:15 - Autocar Professional
Longeveron licenses stem cell patent for heart disease treatment - Investing.com
Longeveron licenses stem cell patent for heart disease treatment By Investing.com - Investing.com Nigeria
Longeveron Licenses US Patent for Advanced Cardiomyogenic Cell Technology from University of Miami - Nasdaq
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease - The Manila Times
Revolutionary Heart Disease Breakthrough: Longeveron Licenses Safer Cardiac Stem Cell Technology - Stock Titan
What makes Longeveron Inc. stock price move sharplyFree Exclusive Stock Market Insights - Newser
Why Longeveron Inc. stock attracts strong analyst attentionLong Term Safe Yield Focus - Newser
Longeveron (LGVN) gets FDA nod to start Phase 2 laromestrocel trial | PLUG SEC FilingForm 424B7 - Stock Titan
Longeveron receives FDA approval for pediatric heart therapy IND By Investing.com - Investing.com South Africa
Longeveron®? Announces U.S. FDA Approval of IND Application for A Phase 2 Pivotal Registration Study Evaluating Laromestrocel as A Treatment of Pediatric Dilated Cardiomyopathy - MarketScreener
Longeveron® announces U.S. FDA approval of IND application - MarketScreener
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) - The Manila Times
Longeveron stock soars after FDA approves IND for heart failure treatment - Investing.com Nigeria
Longeveron stock soars after FDA approves IND for heart failure treatment By Investing.com - Investing.com South Africa
Longeveron Inc. Receives FDA Approval for IND Application to Advance Clinical Trial of Stem Cell Therapy for Pediatric Dilated Cardiomyopathy - Nasdaq
Breakthrough: FDA Fast-Tracks New Stem Cell Therapy for Fatal Children's Heart Condition - Stock Titan
Longeveron (NASDAQ:LGVN) Shares Down 1.5% – What’s Next? - Defense World
Longeveron appoints Than Powell as chief business officer - Investing.com
Longeveron (LGVN) Appoints New Chief Business Officer to Lead Strategic Initiatives | LGVN Stock News - GuruFocus
Longeveron Inc Azioni (LGVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):